TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01325350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation A
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation B
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation C
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Study: NCT04670289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TenoMiR (Medium Dose)
Description: Mimic of miR29a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TenoMiR (High Dose)
Description: Mimic of miR29a
Study: NCT01325350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minoxidil 2% solution
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Study: NCT00505050

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Disease Program Management
Description: This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms.
Study: NCT02477592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: individualized substrate modification
Description: CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stepwise ablation
Description: CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
Study: NCT00778596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo priming
Description: Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
Study: NCT02559037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Description: Acupuncture acupoints: CV12, bilateral ST36, ST37, SP6, SP9, SP4, LR3 and LI3. Disposable acupuncture auxiliary device and 0.30\*40mm or 0.30\*25mm acupuncture needles (hwato, suzhou medical supplies factory co., LTD.) were used. The needles were directly inserted 20-30mm into the skin and elicited a de-qi sensation. The needle was kept for 30 min.~Moxibustion acupoints: bilateral ST25 and ST36. Using mild-warm moxibustion, The surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint. Moxibustion and acupuncture were performed at the same time, once every other day, three times a week, a total of 12 weeks of treatment. After the treatment, subjects were followed up in the weeks 24, 36 and 48.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture and moxibustion
Description: The acupoints used are same to the experimental group. Same disposable acupuncture auxiliary device and 0.35 \* 40mm acupuncture needle (flat and blunt needle tip, Hwato, Suzhou Medical Supplies Factory Co., Ltd.) was selected. When the needle was pricked to the acupoint, it did not penetrating into the skin. The subject only felt slight pain and do not have the de-qi sensation.~Sham moxibustion : by using the same moxa stick, The surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint. Sham acupuncture and sham moxibustion were performed at the same time. They were treated once every other day, three times a week, a total of 12 weeks. After the treatment, subjects were followed up in the weeks 24, 36 and 48.
Study: NCT04268407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: compare the duration of antbiotic use: 2 day versus 7 day

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin Clavulanate
Description: compare the duration of antbiotic use: 2 day versus 7 day
Study: NCT02118103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Lumbar spinal manipulation
Study: NCT04383301

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracorneal ring segment implantaion as the first stage
Description: Intracorneal ring segment (ICRS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACXL and wafe front guieded TPRK as the second stage
Description: Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
Study: NCT01276158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound used to place arterial line

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler
Description: Doppler used to place arterial line
Study: NCT01455870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 60 mcg/day
Description: exenatide in DUROS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: oral sitagliptin 100 mg/day
Study: NCT01086670

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Exercise
Description: Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
Study: NCT01897337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
Study: NCT00956839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Description: Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Description: Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Description: Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months
Study: NCT01053156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline hydrochloride
Description: Minocycline hydrochloride dosed orally once a day for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given daily for 3 months.
Study: NCT01988467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to second hand smoking
Description: The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to second hand smoking
Description: The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
Study: NCT04670289

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT03714087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T1 before aligner
Description: The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T2 after the aligner
Description: The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Historic control group
Study: NCT02642263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Postpartum uterotonic drug
Study: NCT00230880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: follow-up phone counseling
Description: 9 calls over 12 months
Study: NCT02296723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir Hydrochloride
Description: Valganciclovir Hydrochloride Tablets 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir Hydrochloride
Description: Valganciclovir Hydrochloride Tablets 450 mg
Study: NCT00231452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
Description: Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
Description: Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
Description: Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
Study: NCT02104778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
Study: NCT03814148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LENINGRADO 5 association
Description: 1 coated sustained-release tablet, oral, once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrilix® SR
Description: 1 coated sustained-release tablet, oral, once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natrilix SR Placebo
Description: 1 coated sustained-release tablet, oral, once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leningrado 5 association Placebo
Description: 1 coated sustained-release tablet, oral, once a day.
Study: NCT00684723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg Tablets
Description: 40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin (Mevacor®) 40 mg Tablets
Description: 40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
Study: NCT03013075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with Bupivacaine heavy and Morphine
Description: Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine heavy and Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthetics
Study: NCT00697645

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep TMS (Transcranial magnetic stimulation)
Description: All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brainsway Deep TMS
Description: Deep TMS applied over the motor strip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway Deep TMS
Description: Deep TMS applied over the motor strip
Study: NCT03746587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: Arimoclomol in 3 different dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: Arimoclomol in 3 different dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: Arimoclomol in 3 different dosages

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsule
Study: NCT03227406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Subjects are kept awake all night.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Participants are given a 90-minute nap opportunity in the early afternoon.
Study: NCT02179125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RePneu Lung Volume Reduction Coil System
Description: Bronchoscopic lung volume reduction treatment with Coils.
Study: NCT01614301

Intervention type: DRUG
Group type: OTHER
Intervention: dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus
Description: Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus
Description: Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity
Study: NCT03984708

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood sample, skin biopsy
Study: NCT03812302

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68-Ga HA-DOTATATE PET/CT
Description: See arm description.
Study: NCT02063373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
Study: NCT03089138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regan Tangjiang
Description: The treatment duration is 3 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regan Tangjiang
Description: The treatment duration is 3 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regan Tangjiang
Description: The treatment duration is 3 consecutive days.
Study: NCT06266624

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tourniquet Test
Description: Tourniquet Test was performed in patients with HHT
Study: NCT00667147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Abraxane and Daily Vandetanib
Description: Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane every three weeks and daily vandetanib
Description: Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
Study: NCT03814551

Intervention type: BEHAVIORAL
Intervention: Signage
Description: Placement of signage discouraging consumption of beverages with added sugar
Study: NCT04341467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
Study: NCT03378453

Intervention type: DEVICE
Group type: OTHER
Intervention: PET-scan18F-AV-45
Description: The PET-scan18F-AV-45 is a PET-scan dedicated to analyze the amyloid load in the brain with the AV45 tracer by the measurement of the mean cortical SuVr

Intervention type: DEVICE
Group type: OTHER
Intervention: PET-scan18F-AV-45
Description: PET-scan18F-AV-45 already done in another protocol MEMENTO-AMYging
Study: NCT02299414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive therapy
Description: 1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No anti-hypertensive therapy (unless BP is severe)
Description: Treatment will not be started if blood pressure remains \<160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
Study: NCT03154970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Craniocervical flexion training
Description: The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
Study: NCT02776995

Intervention type: OTHER
Group type: OTHER
Intervention: Thermography imaging
Description: Thermography imaging of the treated - irradiated body area.
Study: NCT05195021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDDY
Description: EDDY (VDW) sonic irrigation activation system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDDY
Description: EDDY (VDW) sonic irrigation activation system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser device
Description: 980-nm diode laser device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser device
Description: 980-nm diode laser device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional irrigation
Description: Conventional root canal irrigation with 31-guage side port needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional irrigation
Description: Conventional root canal irrigation with 31-guage side port needle
Study: NCT03984708

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood sample, skin biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: Indirect calorimetry
Description: Measurement of energy expenditure by indirect calorimetry

Intervention type: OTHER
Group type: OTHER
Intervention: Electrical bioimpedance
Description: Measurement of electrical bioimpedance
Study: NCT03143257

Intervention type: DEVICE
Intervention: Sophono Bone Conduction Hearing Systems
Description: The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of Bone Conduction (BC) of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear.